Do analysts rate DH or AIFF?

Definitive Healthcare currently has a consensus target price of $1.47, suggesting a potential upside of 50.15%. Given Definitive Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Definitive Healthcare is more favorable than Firefly Neuroscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Definitive Healthcare 3 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 1.90 Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate AIFF or CCLD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CareCloud 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts prefer DRIO or AIFF?

DarioHealth presently has a consensus price target of $10.00, indicating a potential upside of 72.41%. Given DarioHealth's stronger consensus rating and higher possible upside, equities analysts plainly believe DarioHealth is more favorable than Firefly Neuroscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DarioHealth 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to DRIO or AIFF?

In the previous week, DarioHealth and DarioHealth both had 3 articles in the media. DarioHealth's average media sentiment score of 0.00 equaled Firefly Neuroscience'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DarioHealth 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Firefly Neuroscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AIFF or HIT?

Health In Tech has a consensus target price of $3.50, indicating a potential upside of 373.10%. Given Health In Tech's stronger consensus rating and higher possible upside, analysts plainly believe Health In Tech is more favorable than Firefly Neuroscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Health In Tech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Does the media refer more to AIFF or HIT?

In the previous week, Health In Tech had 9 more articles in the media than Firefly Neuroscience. MarketBeat recorded 12 mentions for Health In Tech and 3 mentions for Firefly Neuroscience. Firefly Neuroscience's average media sentiment score of 0.00 beat Health In Tech's score of -0.33 indicating that Firefly Neuroscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Firefly Neuroscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Health In Tech 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ONMD or AIFF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OneMedNet 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ONMD or AIFF?

In the previous week, OneMedNet had 8 more articles in the media than Firefly Neuroscience. MarketBeat recorded 11 mentions for OneMedNet and 3 mentions for Firefly Neuroscience. OneMedNet's average media sentiment score of 0.35 beat Firefly Neuroscience's score of 0.00 indicating that OneMedNet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OneMedNet 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Firefly Neuroscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Firefly Neuroscience (AIFF) Competitors

$1.19 -0.02 (-1.65%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.18 -0.01 (-1.09%)

As of 10/9/2026 07:32 PM Eastern

Compare

AIFF vs. DH, CCLD, DRIO, HIT, and ONMD

Should you buy Firefly Neuroscience stock or one of its competitors? Firefly Neuroscience's main competitors and comparable companies include Definitive Healthcare (DH), CareCloud (CCLD), DarioHealth (DRIO), Health In Tech (HIT), and OneMedNet (ONMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Firefly Neuroscience compare to Definitive Healthcare?

Definitive Healthcare (NASDAQ:DH) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

98.7% of Definitive Healthcare shares are owned by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are owned by institutional investors. 17.1% of Definitive Healthcare shares are owned by company insiders. Comparatively, 6.9% of Firefly Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Definitive Healthcare currently has a consensus target price of $1.47, suggesting a potential upside of 50.15%. Given Definitive Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Definitive Healthcare is more favorable than Firefly Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definitive Healthcare	3 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	1.90
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Firefly Neuroscience had 2 more articles in the media than Definitive Healthcare. MarketBeat recorded 3 mentions for Firefly Neuroscience and 1 mentions for Definitive Healthcare. Definitive Healthcare's average media sentiment score of 0.00 equaled Firefly Neuroscience'saverage media sentiment score.

Company	Overall Sentiment
Definitive Healthcare	Neutral
Firefly Neuroscience	Neutral

Definitive Healthcare has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Firefly Neuroscience has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

Firefly Neuroscience has lower revenue, but higher earnings than Definitive Healthcare. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Definitive Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definitive Healthcare	$232.70M	0.45	-$138.93M	-$1.60	N/A
Firefly Neuroscience	$1.14M	16.38	-$19.88M	-$0.59	N/A

Definitive Healthcare has a net margin of -72.28% compared to Firefly Neuroscience's net margin of -506.23%. Definitive Healthcare's return on equity of 3.55% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definitive Healthcare	-72.28%	3.55%	1.63%
Firefly Neuroscience	-506.23%	-90.17%	-72.05%

Summary

Definitive Healthcare beats Firefly Neuroscience on 11 of the 15 factors compared between the two stocks.

How does Firefly Neuroscience compare to CareCloud?

Firefly Neuroscience (NASDAQ:AIFF) and CareCloud (NASDAQ:CCLD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CareCloud	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

5.0% of Firefly Neuroscience shares are owned by institutional investors. Comparatively, 10.2% of CareCloud shares are owned by institutional investors. 6.9% of Firefly Neuroscience shares are owned by company insiders. Comparatively, 14.8% of CareCloud shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Firefly Neuroscience had 2 more articles in the media than CareCloud. MarketBeat recorded 3 mentions for Firefly Neuroscience and 1 mentions for CareCloud. Firefly Neuroscience's average media sentiment score of 0.00 equaled CareCloud'saverage media sentiment score.

Company	Overall Sentiment
Firefly Neuroscience	Neutral
CareCloud	Neutral

CareCloud has a net margin of 6.21% compared to Firefly Neuroscience's net margin of -506.23%. CareCloud's return on equity of 27.07% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Firefly Neuroscience	-506.23%	-90.17%	-72.05%
CareCloud	6.21%	27.07%	14.56%

Firefly Neuroscience has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, CareCloud has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market.

CareCloud has higher revenue and earnings than Firefly Neuroscience. Firefly Neuroscience is trading at a lower price-to-earnings ratio than CareCloud, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Firefly Neuroscience	$1.14M	16.38	-$19.88M	-$0.59	N/A
CareCloud	$128.64M	0.66	$10.80M	$0.07	28.57

Summary

CareCloud beats Firefly Neuroscience on 12 of the 14 factors compared between the two stocks.

How does Firefly Neuroscience compare to DarioHealth?

DarioHealth (NASDAQ:DRIO) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

DarioHealth presently has a consensus price target of $10.00, indicating a potential upside of 72.41%. Given DarioHealth's stronger consensus rating and higher possible upside, equities analysts plainly believe DarioHealth is more favorable than Firefly Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

DarioHealth has a net margin of -169.87% compared to Firefly Neuroscience's net margin of -506.23%. DarioHealth's return on equity of -54.81% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-169.87%	-54.81%	-33.36%
Firefly Neuroscience	-506.23%	-90.17%	-72.05%

Firefly Neuroscience has lower revenue, but higher earnings than DarioHealth. Firefly Neuroscience is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	2.54	-$41.71M	-$6.13	N/A
Firefly Neuroscience	$1.14M	16.38	-$19.88M	-$0.59	N/A

In the previous week, DarioHealth and DarioHealth both had 3 articles in the media. DarioHealth's average media sentiment score of 0.00 equaled Firefly Neuroscience'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DarioHealth	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Firefly Neuroscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DarioHealth has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Firefly Neuroscience has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

33.4% of DarioHealth shares are held by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are held by institutional investors. 3.5% of DarioHealth shares are held by company insiders. Comparatively, 6.9% of Firefly Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

DarioHealth beats Firefly Neuroscience on 10 of the 14 factors compared between the two stocks.

How does Firefly Neuroscience compare to Health In Tech?

Firefly Neuroscience (NASDAQ:AIFF) and Health In Tech (NASDAQ:HIT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Health In Tech has a net margin of 0.00% compared to Firefly Neuroscience's net margin of -506.23%. Health In Tech's return on equity of 0.00% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Firefly Neuroscience	-506.23%	-90.17%	-72.05%
Health In Tech	N/A	N/A	N/A

Health In Tech has higher revenue and earnings than Firefly Neuroscience. Health In Tech is trading at a lower price-to-earnings ratio than Firefly Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Firefly Neuroscience	$1.14M	16.38	-$19.88M	-$0.59	N/A
Health In Tech	$32.83M	1.48	-$4.59M	-$0.07	N/A

In the previous week, Health In Tech had 9 more articles in the media than Firefly Neuroscience. MarketBeat recorded 12 mentions for Health In Tech and 3 mentions for Firefly Neuroscience. Firefly Neuroscience's average media sentiment score of 0.00 beat Health In Tech's score of -0.33 indicating that Firefly Neuroscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Firefly Neuroscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Health In Tech	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Health In Tech has a consensus target price of $3.50, indicating a potential upside of 373.10%. Given Health In Tech's stronger consensus rating and higher possible upside, analysts plainly believe Health In Tech is more favorable than Firefly Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Health In Tech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

5.0% of Firefly Neuroscience shares are owned by institutional investors. 6.9% of Firefly Neuroscience shares are owned by insiders. Comparatively, 77.7% of Health In Tech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Firefly Neuroscience has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market. Comparatively, Health In Tech has a beta of 2.81, suggesting that its share price is 181% more volatile than the broader market.

Summary

Health In Tech beats Firefly Neuroscience on 13 of the 17 factors compared between the two stocks.

How does Firefly Neuroscience compare to OneMedNet?

OneMedNet (NASDAQ:ONMD) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Firefly Neuroscience has a net margin of -506.23% compared to OneMedNet's net margin of -584.20%. OneMedNet's return on equity of 0.00% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OneMedNet	-584.20%	N/A	-521.20%
Firefly Neuroscience	-506.23%	-90.17%	-72.05%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OneMedNet	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

OneMedNet has higher revenue and earnings than Firefly Neuroscience. OneMedNet is trading at a lower price-to-earnings ratio than Firefly Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OneMedNet	$1.36M	18.75	-$2.80M	-$1.60	N/A
Firefly Neuroscience	$1.14M	16.38	-$19.88M	-$0.59	N/A

In the previous week, OneMedNet had 8 more articles in the media than Firefly Neuroscience. MarketBeat recorded 11 mentions for OneMedNet and 3 mentions for Firefly Neuroscience. OneMedNet's average media sentiment score of 0.35 beat Firefly Neuroscience's score of 0.00 indicating that OneMedNet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OneMedNet	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Firefly Neuroscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.0% of OneMedNet shares are owned by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are owned by institutional investors. 50.2% of OneMedNet shares are owned by insiders. Comparatively, 6.9% of Firefly Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

OneMedNet has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Firefly Neuroscience has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Summary

OneMedNet beats Firefly Neuroscience on 8 of the 13 factors compared between the two stocks.

Get Firefly Neuroscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIFF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIFF vs. The Competition

Export

Metric	Firefly Neuroscience	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.99M	$1.81B	$7.16B	$13.21B
Dividend Yield	N/A	3.95%	2.53%	16.37%
P/E Ratio	-2.02	21.78	275.30	26.16
Price / Sales	16.38	95.30	635.97	107.53
Price / Cash	N/A	31.98	76.38	53.09
Price / Book	2.09	6.25	11.22	6.33
Net Income	-$19.88M	-$19.09M	$3.50B	$382.15M
7 Day Performance	-12.50%	-0.80%	-0.89%	-1.40%
1 Month Performance	11.21%	1.00%	-4.42%	-3.47%
1 Year Performance	-54.75%	-19.78%	7.03%	1.18%

Firefly Neuroscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIFF Firefly Neuroscience	0.265 of 5 stars	$1.19 -1.7%	N/A	-59.5%	$18.99M	$1.14M	N/A	17	Short Interest Increase
DH Definitive Healthcare	3.6746 of 5 stars	$0.91 -1.9%	$1.47 +61.3%	-68.2%	$99.27M	$241.52M	N/A	686	News Coverage Positive News
CCLD CareCloud	2.0813 of 5 stars	$2.04 -1.9%	N/A	-42.0%	$88.39M	$120.50M	29.14	3,650
DRIO DarioHealth	3.6219 of 5 stars	$7.04 +6.3%	$10.00 +42.0%	-63.0%	$64.87M	$21.00M	N/A	165	Analyst Forecast
HIT Health In Tech	2.7171 of 5 stars	$0.82 -3.7%	$3.50 +326.5%	-78.5%	$53.79M	$32.83M	N/A	91	Analyst Revision Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIFF) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Firefly Neuroscience (AIFF) Competitors

AIFF vs. DH, CCLD, DRIO, HIT, and ONMD

How does Firefly Neuroscience compare to Definitive Healthcare?

Summary

How does Firefly Neuroscience compare to CareCloud?

Summary

How does Firefly Neuroscience compare to DarioHealth?

Summary

How does Firefly Neuroscience compare to Health In Tech?

Summary

How does Firefly Neuroscience compare to OneMedNet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFF vs. The Competition

Firefly Neuroscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Firefly Neuroscience (AIFF) Competitors

AIFF vs. DH, CCLD, DRIO, HIT, and ONMD

How does Firefly Neuroscience compare to Definitive Healthcare?

Do institutionals and insiders have more ownership in DH or AIFF?

Do analysts rate DH or AIFF?

Does the media prefer DH or AIFF?

Which has more volatility & risk, DH or AIFF?

Which has better earnings and valuation, DH or AIFF?

Is DH or AIFF more profitable?

Summary

How does Firefly Neuroscience compare to CareCloud?

Do analysts rate AIFF or CCLD?

Do institutionals & insiders believe in AIFF or CCLD?

Does the media favor AIFF or CCLD?

Is AIFF or CCLD more profitable?

Which has more volatility and risk, AIFF or CCLD?

Which has higher valuation and earnings, AIFF or CCLD?

Summary

How does Firefly Neuroscience compare to DarioHealth?

Do analysts prefer DRIO or AIFF?

Is DRIO or AIFF more profitable?

Which has better earnings & valuation, DRIO or AIFF?

Does the media refer more to DRIO or AIFF?

Which has more volatility and risk, DRIO or AIFF?

Do insiders and institutionals believe in DRIO or AIFF?

Summary

How does Firefly Neuroscience compare to Health In Tech?

Is AIFF or HIT more profitable?

Which has better valuation and earnings, AIFF or HIT?

Does the media refer more to AIFF or HIT?

Do analysts rate AIFF or HIT?

Do insiders & institutionals believe in AIFF or HIT?

Which has more volatility and risk, AIFF or HIT?

Summary

How does Firefly Neuroscience compare to OneMedNet?

Is ONMD or AIFF more profitable?

Do analysts recommend ONMD or AIFF?

Which has preferable earnings & valuation, ONMD or AIFF?

Does the media refer more to ONMD or AIFF?

Do institutionals and insiders believe in ONMD or AIFF?

Which has more risk & volatility, ONMD or AIFF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFF vs. The Competition

Firefly Neuroscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools